Gilead's HIV Quad Pill Passes Tolerability Test, But Not With A Straight "A"
Executive Summary
By and large, Gilead's latest Phase II results for its fixed-dose, four-drug "Quad" regimen for HIV and stand-alone data on its novel GS-9350 booster satisfied clinicians and analysts when it came to the commercially crucial tolerability test
You may also be interested in...
Gilead Clarifies Quad Will Come First, Over Detailing For Triple Combo Complera
Company is pursuing priority review, eyes FDA approval in mid-2012. If Quad is cleared, newly approved Complera will take back seat.
Gilead Clarifies Quad Will Come First, Over Detailing For Triple Combo Complera
Company is pursuing priority review, eyes FDA-approval in mid-2012. If Quad is cleared, newly-approved Complera will take back seat.
Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up
Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.